Jeffrey J Kirshner

Summary

Publications

  1. pmc Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base
    Jeffrey J Kirshner
    Hematology Oncology Associates of Central New York, Community Clinical Oncology Program, East Syracuse, NY, USA
    J Clin Oncol 30:1974-9. 2012
  2. ncbi Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy
    Jeffrey Kirshner
    Hematology Oncology Associates of Central New York, East Syracuse, New York 13057, USA
    Oncologist 9:25-32. 2004
  3. ncbi Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline
    Naren Ramakrishna
    Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando Edith A Perez, Mayo Clinic, Jacksonville Jennifer Levinson, Ponte Vedra Beach, FL Sarah Temin, American Society of Clinical Oncology, Alexandria, VA Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center Francisco J Esteva, New York University Cancer Institute, New York Jeffrey J Kirshner, Hematology Oncology Associates of Central New York, East Syracuse, NY Jennie R Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA Nancy E Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA Sharon H Giordano and Ana M Gonzalez Angulo, University of Texas MD Anderson Cancer Center, Houston Debra A Patt, Texas Oncology, Austin, TX Ian Krop, Eric P Winter, and Nancy U Lin, Dana Farber Cancer Institute, Boston, MA and Jane Perlmutter, Ann Arbor, MI
    J Clin Oncol 32:2100-8. 2014
  4. pmc A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors
    Jennifer S Gewandter
    Department of Anesthesiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 604, Rochester, NY, 14642, USA
    Support Care Cancer 22:1807-14. 2014
  5. ncbi Weekly paclitaxel in women age 65 and above with metastatic breast cancer
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Breast Cancer Res Treat 73:85-8. 2002
  6. ncbi Association of coping style, pain, age and depression with fatigue in women with primary breast cancer
    Katrin Reuter
    Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Germany
    Psychooncology 15:772-9. 2006

Research Grants

  1. SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
    Jeffrey Kirshner; Fiscal Year: 2004
  2. SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
    Jeffrey Kirshner; Fiscal Year: 2007
  3. SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
    Jeffrey Kirshner; Fiscal Year: 2008

Collaborators

Detail Information

Publications6

  1. pmc Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base
    Jeffrey J Kirshner
    Hematology Oncology Associates of Central New York, Community Clinical Oncology Program, East Syracuse, NY, USA
    J Clin Oncol 30:1974-9. 2012
    ..Pegfilgrastim-induced bone pain is a significant clinical problem that may result in discontinuation of pegfilgrastim and lead to less effective chemotherapy dosing. Interventions for pegfilgrastim-induced bone pain are needed...
  2. ncbi Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy
    Jeffrey Kirshner
    Hematology Oncology Associates of Central New York, East Syracuse, New York 13057, USA
    Oncologist 9:25-32. 2004
    ..The incidence and severity of prechemotherapy anemia and chemotherapy-induced anemia experienced by women treated with adjuvant doxorubicin and cyclophosphamide (AC) therapy for stage II and III breast cancer are described...
  3. ncbi Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline
    Naren Ramakrishna
    Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando Edith A Perez, Mayo Clinic, Jacksonville Jennifer Levinson, Ponte Vedra Beach, FL Sarah Temin, American Society of Clinical Oncology, Alexandria, VA Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center Francisco J Esteva, New York University Cancer Institute, New York Jeffrey J Kirshner, Hematology Oncology Associates of Central New York, East Syracuse, NY Jennie R Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA Nancy E Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA Sharon H Giordano and Ana M Gonzalez Angulo, University of Texas MD Anderson Cancer Center, Houston Debra A Patt, Texas Oncology, Austin, TX Ian Krop, Eric P Winter, and Nancy U Lin, Dana Farber Cancer Institute, Boston, MA and Jane Perlmutter, Ann Arbor, MI
    J Clin Oncol 32:2100-8. 2014
    ..To provide formal expert consensus-based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer...
  4. pmc A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors
    Jennifer S Gewandter
    Department of Anesthesiology, University of Rochester Medical Center, 601 Elmwood Ave, Box 604, Rochester, NY, 14642, USA
    Support Care Cancer 22:1807-14. 2014
    ..The FDA has yet to approve a therapy for CIPN. The aim of this multicenter, phase III, randomized, double-blind, placebo-controlled trial was to investigate the efficacy of 2% ketamine plus 4% amitriptyline (KA) cream for reducing CIPN...
  5. ncbi Weekly paclitaxel in women age 65 and above with metastatic breast cancer
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Breast Cancer Res Treat 73:85-8. 2002
    ..Response rates and overall survival times were comparable in the two age groups (<65 and > or =65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer...
  6. ncbi Association of coping style, pain, age and depression with fatigue in women with primary breast cancer
    Katrin Reuter
    Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Germany
    Psychooncology 15:772-9. 2006
    ..The relationship between cancer related fatigue, age and coping styles requires further exploration within longitudinal studies...

Research Grants3

  1. SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
    Jeffrey Kirshner; Fiscal Year: 2004
    ..Joseph's Hospital Health Center, Syracuse, New York ..
  2. SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
    Jeffrey Kirshner; Fiscal Year: 2007
    ..Joseph's Hospital Health Center, Syracuse, New York [unreadable] [unreadable] [unreadable]..
  3. SYRACUSE HEMATOLOGY-ONCOLOGY CCOP
    Jeffrey Kirshner; Fiscal Year: 2008
    ..Joseph's Hospital Health Center, Syracuse, New York [unreadable] [unreadable] [unreadable]..